Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
548.74-0.38 (-0.07%)
At close: 04:03PM EDT
542.32 -6.42 (-1.17%)
After hours: 05:23PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close549.12
Open553.89
Bid399.98 x 1100
Ask547.05 x 800
Day's Range542.32 - 556.32
52 Week Range462.61 - 832.70
Volume79,714
Avg. Volume173,056
Market Cap16.411B
Beta (5Y Monthly)0.93
PE Ratio (TTM)2.49
EPS (TTM)220.48
Earnings DateApr 27, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est690.00
  • Insider Monkey

    12 Best Healthcare Stocks To Buy Now

    In this piece, we will take a look at the twelve best healthcare stocks to buy now. If you want to skip the details and head on to the top stocks in this list, then take a look at 5 Best Healthcare Stocks To Buy Now. Healthcare stocks are proving to be resilient in the […]

  • Business Wire

    Bio-Rad Acquires Curiosity Diagnostics

    HERCULES, Calif., August 03, 2022--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland, based developer of innovative technology solutions for the medical diagnostic and healthcare markets, for a total consideration of up to $170 mil

  • Zacks

    Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up

    Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.

Advertisement
Advertisement